参考文献/References:
[1]Simon DK,Tanner CM,Brundin P.Parkinson Disease Epidemiology,Pathology,Genetics,and Pathophysiology[J].Clin Geriatr Med,2020,36(1):1-12. [2]Homayoun H.Parkinson Disease[J].Ann Intern Med,2018,169(5):C33-C48. [3]Poewe W,Seppi K,Tanner CM,et al.Parkinson disease[J].Nat Rev Dis Primers,2017(3):17013. [4]Dorsey ER,Constantinescu R,Thompson JP,et al.Projected number of people with Parkinson disease in the most populous nations,2005 through 2030[J].Neurology,2007,68(5):384-386. [5]Lee HP,Zhu X,Liu G,et al.Divalent metal transporter,iron,and Parkinson’s disease:a pathological relationship[J].Cell Res,2010,20(4):397-399. [6]Ingrassia R,Garavaglia B,Memo M.DMT1 Expression and Iron Levels at the Crossroads Between Aging and Neurodegeneration[J].Front Neurosci,2019(13):575. [7]Deng H,Wang P,Jankovic J.The genetics of Parkinson disease[J].Ageing Res Rev,2018(42):72-85. [8]Kalinderi K,Bostantjopoulou S,Fidani L.The genetic background of Parkinson’s disease:current progress and future prospects[J].Acta Neurol Scand,2016,134(5):314-326. [9]Schapira A,Chaudhuri KR,Jenner P.Non-motor features of Parkinson disease[J].Nat Rev Neurosci,2017,18(7):435-450. [10]Chase BA,Markopoulou K.Olfactory Dysfunction in Familial and Sporadic Parkinson’s Disease[J].Front Neurol,2020(11):447. [11]Sommer A,Marxreiter F, Krach F,et al.Th17 Lymphocytes Induce Neuronal Cell Death in a Human iPSC-Based Model of Parkinson’s Disease[J].Cell Stem Cell,2018,23(1):123-131. [12]Barba C,Alexopoulos H.Parkinsonism in autoimmune diseases[J].Int Rev Neurobiol,2019(149):419-452. [13]Tan EK,Chao YX,West A,et al.Parkinson disease and the immune system-associations,mechanisms and therapeutics[J].Nat Rev Neurol,2020,16(6):303-318. [14]Hirsch EC,Standaert DG.Ten Unsolved Questions About Neuroinflammation in Parkinson’s Disease[J].Mov Disord,2021,36(1):16-24. [15]Kustrimovic N,Comi C,Magistrelli L,et al.Parkinson’s disease patients have a complex phenotypic and functional Th1 bias:cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naive and drug-treated patients[J].J Neuroinflammation,2018,15(1):205. [16]Yang L,Mao K,Yu H,et al.Neuroinflammatory Responses and Parkinson’ Disease:Pathogenic Mechanisms and Therapeutic Targets[J].J Neuroimmune Pharmacol,2020,15(4):830-837. [17]Ma A,Lau KK,Thyagarajan D.Voice changes in Parkinson’s disease:What are they telling us[J].J Clin Neurosci,2020(72):1-7. [18]Umemoto G,Furuya H.Management of Dysphagia in Patients with Parkinson’s Disease and Related Disorders[J].Intern Med,2020,59(1):7-14.
相似文献/References:
[1]王姝,莫英绪,王大成.帕金森病发病因素的研究现状[J].医学信息,2018,31(01):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
WANG Shu,MO Ying-xu,WANG Da-cheng.Research Status of the Factors of Parkinson's Disease[J].Medical Information,2018,31(12):46.[doi:10.3969/j.issn.1006-1959.2018.01.017]
[2]刘 阳,王惠凌,安 迪,等.进行性核上性麻痹1例报告[J].医学信息,2018,31(05):192.[doi:10.3969/j.issn.1006-1959.2018.05.073]
[3]樊 毅.帕金森病嗅觉改变的相关性研究[J].医学信息,2018,31(17):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]
FAN Yi.Correlation Study of Olfactory Changes in Parkinson's Disease[J].Medical Information,2018,31(12):95.[doi:10.3969/j.issn.1006-1959.2018.17.029]
[4]刘 菲,胡玉婷,刘 静,等.原代小鼠小胶质细胞培养及尼古丁抑制肿瘤坏死因子α分泌的研究[J].医学信息,2019,32(02):111.[doi:10.3969/j.issn.1006-1959.2019.02.031]
Liu Fei,Hu Yu-ting,Liu Jing,et al.A Study of Primary Mouse Microglia Cell Culture and Nicotine Inhibition the Secretion of Tumor Necrosis Factor Alpha[J].Medical Information,2019,32(12):111.[doi:10.3969/j.issn.1006-1959.2019.02.031]
[5]陶广林,马善新,廖 媚.A型肉毒毒素应用于神经性疼痛的研究[J].医学信息,2020,33(09):24.[doi:10.3969/j.issn.1006-1959.2020.09.009]
TAO Guang-lin,MA Shan-xin,LIAO Mei.Study on the Application of Botulinum Toxin A in Neuropathic Pain[J].Medical Information,2020,33(12):24.[doi:10.3969/j.issn.1006-1959.2020.09.009]
[6]陈凤全.帕金森病的诊治现状及进展[J].医学信息,2020,33(12):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
CHEN Feng-quan.Status and Progress of Diagnosis and Treatment of Parkinson’s Disease[J].Medical Information,2020,33(12):43.[doi:10.3969/j.issn.1006-1959.2020.12.014]
[7]邓伟胜,楼云龙,苏中振.正电子发射断层扫描PET/CT在帕金森病患者早期诊断中的应用[J].医学信息,2020,33(18):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
DENG Wei-sheng,LOU Yun-long,SU Zhong-zhen.Application of Positron Emission Tomography PET/CT in Early Diagnosis of Parkinson’s Disease[J].Medical Information,2020,33(12):170.[doi:10.3969/j.issn.1006-1959.2020.18.057]
[8]郭 青,何前松,胡斐然,等.大黄酚通过TLR4/NF-kB信号通路途径调控小胶质细胞炎性反应[J].医学信息,2020,33(19):51.[doi:10.3969/j.issn.1006-1959.2020.19.016]
GUO Qing,HE Qian-song,HU Fei-ran,et al.Chrysophanol Regulates Microglial Inflammatory Response Through TLR4/NF-kB Signaling Pathway[J].Medical Information,2020,33(12):51.[doi:10.3969/j.issn.1006-1959.2020.19.016]
[9]贺诗佳,孙 玲,张树山.脑内肾素-血管紧张素系统在帕金森病发病机制中的作用研究[J].医学信息,2021,34(03):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
HE Shi-jia,SUN Ling,ZHANG Shu-shan.Study on the Role of Renin-angiotensin System in the Pathogenesis of Parkinson’s Disease[J].Medical Information,2021,34(12):34.[doi:10.3969/j.issn.1006-1959.2021.03.011]
[10]许红玉,梅育嘉,罗杰峰.神经节苷脂联合复方左旋多巴治疗帕金森病的效果[J].医学信息,2021,34(03):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]
XU Hong-yu,MEI Yu-jia,LUO Jie-feng.The Effect of Ganglioside Combined with Benserazide in the Treatment of Parkinson’s Disease[J].Medical Information,2021,34(12):160.[doi:10.3969/j.issn.1006-1959.2021.03.045]